Infinity Pharmaceuticals

Infinity halts phase II pancreatic cancer study

Friday, January 27, 2012 02:04 PM

After analyzing interim data, Infinity Pharmaceuticals has stopped its phase II study comparing saridegib (IPI-926) in combination with gemcitabine to a placebo plus gemcitabine as treatment for metastatic pancreatic cancer.

More... »


Infinity, Mundipharma extend global alliance

Tuesday, November 29, 2011 02:39 PM

Infinity Pharmaceuticals has reported that Mundipharma International has committed to providing over $50 million in funding in 2013 for the continued development of IPI-145, Infinity's potent, oral inhibitor of phosphoinositide-3-kinase (PI3K) delta and gamma, as well as development candidates arising out of Infinity's innovative discovery programs. An extension of the companies' global strategic alliance, this funding reflects the broad commercial potential of IPI-145 in both hematologic cancers and inflammatory conditions as well as the continued productivity of Infinity's discovery and development programs.

More... »



CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks worldwide toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs